<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03915366</url>
  </required_header>
  <id_info>
    <org_study_id>19/096</org_study_id>
    <secondary_id>2019-001749-42</secondary_id>
    <secondary_id>EDCTP RIA2017MC-2013EMPIRICAL</secondary_id>
    <secondary_id>U1111-1231-4736</secondary_id>
    <secondary_id>PACTR201904797961340</secondary_id>
    <nct_id>NCT03915366</nct_id>
  </id_info>
  <brief_title>Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia</brief_title>
  <acronym>EMPIRICAL</acronym>
  <official_title>Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia: a Multicenter, Open-label Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario 12 de Octubre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PENTA Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Cocody</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malawi-Liverpool-Wellcome Trust Clinical Research Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eduardo Mondlane University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Investigação em Saúde de Manhiça</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stichting Katholieke Universiteit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barcelona Institute for Global Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lincoln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Teaching Hospital, Lusaka, Zambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zimbabwe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario 12 de Octubre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate whether empirical treatment against cytomegalovirus and tuberculosis
      improves survival of HIV-infected infants with severe pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pneumonia is the main cause of death in Human Immunodeficiency Virus (HIV)-infected children.
      A significant number of undiagnosed or poorly treated HIV-infected children present to health
      services with severe pneumonia. World Health Organization (WHO) guidelines to treat severe
      pneumonia in HIV-infected infants include empirical treatment against common bacteria plus
      Pneumocystis jirovecii. Although this approach has contributed to reducing overall case
      fatality rates, mortality in this particularly vulnerable group remains unacceptably high.
      Autopsy studies in Africa have shown that cytomegalovirus (CMV) infection and tuberculosis
      (TB) are important underdiagnosed and undertreated causes of deaths. Our objective is to
      evaluate whether empirical treatment against cytomegalovirus and tuberculosis improves
      survival of HIV-infected infants with severe pneumonia. A randomized factorial clinical trial
      will be conducted in six sub-Saharan African countries to evaluate the safety and efficacy of
      empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants aged 28
      days to 365 days admitted to hospital with severe pneumonia. The primary outcome is
      mortality. All HIV-infected infants will receive standard of care (SoC) pneumonia treatment,
      including antibiotics, cotrimoxazole, and prednisolone. A group of patients will receive SoC,
      another group will receive valganciclovir plus SoC, another group will receive tuberculosis
      treatment plus SoC, and another group will receive valganciclovir, tuberculosis treatment,
      and SoC.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint of the study is all-cause mortality, focusing on the short term (up to 15-days) and long-term (up to 1-year) mortality. Mortality will be calculated using all-cause mortality after the admission over all the trial time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days with oxygen therapy</measure>
    <time_frame>60 days</time_frame>
    <description>1. Duration of oxygen requirements (in days, from the first requirement until definitive withdrawal, being day 1 the first day of oxygen requirement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>2. Cumulative days of hospitalization from discharge to day +365 after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>Serious Adverse Events (SAEs), this is, grade 3 and 4 AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Reactions</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse Reactions (AR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Notable Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events (AEs) requiring stop of investigational medical product (IMP), all AEs relevant for risk/benefit ratio, including infections, liver toxicity, neurological and optic toxicity, renal, hematological and any AE grade 1, 2, 3 or 4 that the investigator estimates to be relevant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune-reconstitution inflammatory syndrome</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of TB-related immune-reconstitution inflammatory syndrome (IRIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline cytomegalovirus prevalence</measure>
    <time_frame>30 days</time_frame>
    <description>Baseline prevalence of CMV infection and CMV-attributable pneumonia (based in a CMV viral load threshold) in recruited HIV-infected infants with severe pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline tuberculosis prevalence</measure>
    <time_frame>60 days</time_frame>
    <description>Baseline prevalence of microbiological confirmed and unconfirmed TB (according to Graham criteria, Updated Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children 2015) in recruited HIV-infected patients with severe pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tuberculosis incidence</measure>
    <time_frame>1 year</time_frame>
    <description>New confirmed and unconfirmed TB cases according to Graham criteria during 1-year of follow-up among patients without TB-T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deaths attributable to tuberculosis</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of confirmed and unconfirmed TB, according to Graham criteria, in died children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMV prevalence in died participants</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of CMV infection in died children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMV Molecular response to treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Reduction of quantitative CMV viral load in blood and saliva in infants treated with valganciclovir from enrollment to day +15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB-lipoarabinomannan (LAM) sensitivity and specificity</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the diagnostic accuracy (sensitivity and specificity) of TB-LAM for the diagnosis of confirmed TB (reference: positive Xpert Mycobacterium tuberculosis (MTB)/RIF Ultra in feces and/or NPA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-adjusted life expectancy</measure>
    <time_frame>1 year</time_frame>
    <description>Economic evaluation for quality-adjusted life expectancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient cost</measure>
    <time_frame>1 year</time_frame>
    <description>Economic evaluation of the treatments (per-patient cost)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">624</enrollment>
  <condition>Pneumonia</condition>
  <condition>HIV/AIDS</condition>
  <condition>Tuberculosis</condition>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>Standard of Care (SoC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment for severe pneumonia and pneumonia in HIV-infected infants:
Ceftriaxone 80 mg/k/day or Ampicillin plus Gentamicin ampicillin 50 mg/kg, or benzylpenicillin 50,000 unit/kg im/iv every six hours plus Gentamicin 7.5 mg/kg/im or iv once a day Cotrimoxazole trimethoprim (TMP) 8mg/kg/dose + sulfamethoxazole (SMX) 40mg/kg/dose three times daily Prednisolone 2mg/kg during 7 days, plus 1mg/kg other 7 days, plus 0.5 mg/kg for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valganciclovir plus SoC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for cytomegalovirus (CMV) Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, and Standard or Care as described in Control Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tuberculosis Treatment plus SoC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for tuberculosis Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Plus Standard of Care described in the Control Group
Doses of tuberculosis treatment:
Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.
Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.
Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tuberculosis Treatment plus Valganciclovir plus SoC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for CMV and for tuberculosis. Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, Plus Standard of Care described in the Control Group
Doses of tuberculosis treatment:
Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.
Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.
Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir Oral Solution [Valcyte]</intervention_name>
    <description>Treatment for CMV</description>
    <arm_group_label>Tuberculosis Treatment plus Valganciclovir plus SoC</arm_group_label>
    <arm_group_label>Valganciclovir plus SoC</arm_group_label>
    <other_name>Treatment for CMV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tuberculostatic Agents</intervention_name>
    <description>Treatment for tuberculosis</description>
    <arm_group_label>Tuberculosis Treatment plus SoC</arm_group_label>
    <arm_group_label>Tuberculosis Treatment plus Valganciclovir plus SoC</arm_group_label>
    <other_name>Treatment for TB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 28 days to 365 days of age

          2. Pneumonia defined as chest indrawing or fast breathing for age, for infants 28 to 60
             days of age ≥60 breaths per minute and for infants 61 to 365 days of age, ≥50 breaths
             per minute.

          3. Current hospitalization due to pneumonia with criteria for parenteral antibiotics (1
             or more criteria)

               1. Chest indrawing with HIV infection

               2. No improvement with oral treatment.

               3. One or more danger signs according to WHO 5,44,45

                    -  Central cyanosis or saturation of O2 &lt;90%

                    -  Severe respiratory distress, e.g. grunting or very severe chest indrawing

                    -  Signs of pneumonia with a general danger sign:

                    -  Unable to drink or breastfeed

                    -  Persisting vomiting

                    -  Convulsions in the last 24 hours

                    -  Lethargic or unconscious

                    -  Stridor while calm

                    -  Severe malnutrition

          4. HIV-confirmed infection (with at least one molecular method: DNA polymerase chain
             reaction (PCR) or RNA PCR/viral load).

          5. Informed consent obtained

        Exclusion Criteria:

          1. Clinical TB (pulmonary or extrapulmonary) diagnosis, defined as the necessity of TB-T
             prescribed by a physician, at the moment of randomization

          2. Known bacteriologically confirmed TB case (at least one biological specimen positive
             by culture or Xpert MTB/RIF) at the moment of randomization

          3. Patient previously treated for TB or currently on treatment for TB

          4. Documented evidence of close TB exposure (household contact of a patient with
             documented TB during the lifetime of the child, or currently receiving TB-T)

          5. Pure wheezers defined as a clear clinical improvement after a bronchodilator test
             (give a challenge of rapid-acting inhaled bronchodilator for up to three times 15-20
             minutes apart. Count the breaths and look for chest indrawing again, and then
             re-classify)

          6. Active malignancies

          7. Systemic immunosuppressive medications. Steroids will be considered to be
             immunosuppressing only if &gt;2 mg/kg of prednisone or equivalent during &gt;15 days

          8. Evidence of condition other than HIV and pneumonia which precludes, to the judgment of
             the clinical researcher, enrollment in this trial due to risk for the patient. In case
             of doubt, the Trial Management Team will be contacted to assess eligibility

          9. Less than 2.5 kg of weight

         10. Hb &lt;6 g/dL in the screening blood test or in a test done in the last 48 hours.
             Transfusion is permitted to achieve &gt;6 g/dL if the patient's state allows it. In case
             a transfusion is administered, the patient can be enrolled

         11. Neutropenia &lt;500 /mm3 in the screening blood test or in a test done in the last 48
             hours. Repeating the test is allowed to check eligibility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>365 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cinta Moraleda, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fundación para la Investigación Biomédica del Hospital 12 de Octubre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alfredo Tagarro, MD, PhD</last_name>
    <phone>+34917792621</phone>
    <email>alfredo.tagarro@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pablo Rojo, MD, PhD</last_name>
    <phone>+34917792621</phone>
    <email>pablorojoconejo@aim.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Programme PACCI. Centre Hospitalier Cocody.</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <contact>
      <last_name>Raoul Moh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université de Bourdeaux</name>
      <address>
        <city>Bourdeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSERM</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PENTA Foundation</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malawi Liverpool Welcome Trust. Queen Elizabeth Central Hospital College of Medicine</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
    <contact>
      <last_name>Pui Ying Iroh Tam</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cemtro de Investigaçao em Saúde da Manhiça</name>
      <address>
        <city>Manhiça</city>
        <country>Mozambique</country>
      </address>
    </facility>
    <contact>
      <last_name>Nelson Tembe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Central Maputo</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
    <contact>
      <last_name>Christopher Buck</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stichting Katholieke Universiteit Radboudumc</name>
      <address>
        <city>Nimega</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación para la Investigación Biomédica del Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makerere University - Mulago Hospital</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <contact>
      <last_name>Victor Musiime</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Lincoln</name>
      <address>
        <city>Lincoln</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lusaka Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe Clinical Research Centre</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <contact>
      <last_name>Hilda A Mujuru</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
    <country>France</country>
    <country>Italy</country>
    <country>Malawi</country>
    <country>Mozambique</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Uganda</country>
    <country>United Kingdom</country>
    <country>Zambia</country>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Antitubercular Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After principal results, addressing primary and secondary objectives will be published. A final repository will be chosen for anonymized data sharing, and transparency after the trial is closed, according to the funder (EDCTP) rules and recommendations, unless national laws impede it.</ipd_description>
    <ipd_time_frame>Within 12 months of the completion of the study.</ipd_time_frame>
    <ipd_access_criteria>The repository will be public-available by concrete permission of the Clinical Trial Unit. Those interested in having the database or any of its subsets should provide concrete research proposal that may be accepted under citation condition.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

